What is Leerink Partnrs’ Estimate for CLDX FY2028 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Research analysts at Leerink Partnrs lowered their FY2028 EPS estimates for shares of Celldex Therapeutics in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will post earnings of $0.99 per share for the year, down from their prior forecast of $1.04. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ FY2029 earnings at $6.67 EPS.

CLDX has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Price Performance

CLDX opened at $23.29 on Thursday. Celldex Therapeutics has a fifty-two week low of $22.17 and a fifty-two week high of $53.18. The firm has a market capitalization of $1.55 billion, a P/E ratio of -9.06 and a beta of 1.60. The company’s 50-day moving average is $25.32 and its 200 day moving average is $30.67.

Insider Buying and Selling at Celldex Therapeutics

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were purchased at an average price of $26.82 per share, with a total value of $308,430.00. Following the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLDX. KBC Group NV increased its stake in shares of Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 1,504 shares during the period. Handelsbanken Fonder AB grew its stake in Celldex Therapeutics by 23.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company’s stock valued at $469,000 after buying an additional 2,600 shares in the last quarter. Point72 DIFC Ltd raised its holdings in Celldex Therapeutics by 101.7% during the 3rd quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 7,116 shares during the period. Finally, Creative Planning purchased a new stake in shares of Celldex Therapeutics during the third quarter worth $504,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.